Arcus Biosciences Price to Sales Ratio 2017-2022 | RCUS

Historical PS ratio values for Arcus Biosciences (RCUS) over the last 10 years. The current P/S ratio for Arcus Biosciences as of June 28, 2022 is . For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Arcus Biosciences P/S Ratio Historical Data
Date Stock Price TTM Sales per Share Price to Sales Ratio
2022-06-28 24.42 4.59
2022-03-31 31.56 $5.32 5.94
2021-12-31 40.47 $5.20 7.78
2021-09-30 34.87 $0.58 59.63
2021-06-30 27.46 $1.44 19.06
2021-03-31 28.08 $1.34 20.94
2020-12-31 25.96 $1.24 20.95
2020-09-30 17.14 $1.29 13.30
2020-06-30 24.74 $0.34 73.23
2020-03-31 13.88 $0.34 40.61
2019-12-31 10.10 $0.34 29.49
2019-09-30 9.10 $0.17 55.11
2019-06-30 7.95 $0.23 35.26
2019-03-31 12.49 $0.21 58.12
2018-12-31 10.77 $0.31 35.15
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.815B $0.383B
Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $170.283B 10.36
Bio-Rad Laboratories (BIO.B) United States $14.121B 30.63
QIAGEN (QGEN) Netherlands $10.670B 16.84
Biohaven Pharmaceutical Holding (BHVN) United States $10.157B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.957B 0.00
Emergent Biosolutions (EBS) United States $1.640B 7.02
Myovant Sciences (MYOV) United Kingdom $1.243B 0.00
Zymeworks (ZYME) Canada $0.354B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.098B 0.00
Ambrx Biopharma (AMAM) United States $0.098B 0.00
SQZ Biotechnologies (SQZ) United States $0.095B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00